Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial

• Published in: Vaccine Vol. 34; no. 44; pp. 5314 - 5320
• Main Authors: Flechtner, Jessica Baker, Long, Deborah, Larson, Shane, Clemens, Veronica, Baccari, Amy, Kien, Lena, Chan, Jason, Skoberne, Mojca, Brudner, Matthew, Hetherington, Seth
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 17.10.2016; Elsevier Limited
• Subjects: Adjuvants, Immunologic; Adolescent; Adult; Allergy and Immunology; Antibodies, Viral - blood; Antigens; Clinical trials; Dose-Response Relationship, Immunologic; Enzyme-Linked Immunospot Assay; Female; Herpes Genitalis - immunology; Herpes Genitalis - therapy; Herpes simplex virus; Herpes Simplex Virus Vaccines - administration & dosage; Herpes Simplex Virus Vaccines - immunology; Herpes Simplex Virus Vaccines - therapeutic use; Herpesviridae; Herpesvirus 2, Human - immunology; Humans; Immune response; Immunity, Cellular; Immunization; Immunogenicity; Immunotherapy; Infections; Interferon-gamma - biosynthesis; Inventors; Lesions; Lymphocytes; Male; Membrane Glycoproteins - immunology; Middle Aged; Neutralization; Proteins; Studies; T cell receptors; T-Lymphocytes - immunology; Vaccine; Vaccines; Viral Matrix Proteins - administration & dosage; Viral Matrix Proteins - immunology; Virus Shedding; Young Adult; Vaccine; Immune response; Immunotherapy; Herpes simplex virus
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2016.09.001

Highlights • Cellular and humoral responses were boosted in GEN-003 vaccinated HSV-2 seropositive subjects. • Matrix-M2 adjuvant potentiated the immune responses to ICP4 and gD2 antigens contained in GEN-003. • No immune correlates of anti-viral activity have yet been identified.